Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis

Company Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics.

The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus. Its programs have been directed toward conditions including chronic pulmonary infections in people with cystic fibrosis, as well as bloodstream and other difficult-to-treat bacterial infections. Armata also develops engineered phages and phage-based combination therapies intended to improve antibacterial activity and address resistance.

Armata is headquartered in Marina del Rey, California, and conducts research and clinical-development activities in the United States. The company was formerly known as AmpliPhi Biosciences and adopted the Armata Pharmaceuticals name in 2019. Its operations are led by President and Chief Executive Officer Todd R. Patrick.

Key Stats

• Today's Range: $3.22 to $3.84
• 50-Day Range: $2.78 to $5.84
• 52-Week Range: $2.74 to $14.98
• Volume: 25,319 shs
• Average Volume: 121,670 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

Armata Pharmaceuticals Stock Analysis - MarketRank™

Armata Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Armata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Armata Pharmaceuticals has a consensus price target of $15.00, representing about 328.0% upside from its current price of $3.51.

Amount of Analyst Coverage

Armata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $0.50 to ($2.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Armata Pharmaceuticals is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Armata Pharmaceuticals is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.61% of the float of Armata Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Armata Pharmaceuticals has a short interest ratio ("days to cover") of 8.54.

Change versus previous month

Short interest in Armata Pharmaceuticals has recently decreased by 6.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Armata Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Armata Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

3.57% of the stock of Armata Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:ARMP
• CIK: 921114
• Web: www.armatapharma.com
• Phone: (310) 655-2928
• Fax: 310-665-2963
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Armata Pharmaceuticals: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +345.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 6.74
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 5,763,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A